Searched over 200M research papers
10 papers analyzed
These studies suggest that CBD affects brain activity, connectivity, and neurochemistry, offering potential therapeutic benefits for anxiety, depression, autism spectrum disorder, psychosis, and neuroprotection.
20 papers analyzed
Cannabidiol (CBD), a non-intoxicating compound derived from Cannabis sativa, has garnered significant attention for its potential therapeutic effects on various neuropsychiatric and neurodevelopmental disorders. Research has explored CBD's impact on brain function, revealing its influence on brain connectivity, regional cerebral blood flow, and neurotransmitter systems.
Studies have shown that acute administration of CBD enhances fronto-striatal resting state connectivity in healthy volunteers, compared to both placebo and THC, the main psychoactive component of cannabis. This suggests that CBD may positively influence brain networks involved in cognitive processes.
In individuals at high risk for psychosis and patients with established psychosis, CBD has been found to modulate brain activity, showing intermediate effects between placebo and healthy controls during cognitive tasks. This modulation includes changes in functional networks relevant to psychiatric disorders, indicating potential therapeutic benefits.
Functional neuroimaging studies have demonstrated that CBD significantly decreases subjective anxiety and increases mental sedation. These effects are associated with decreased activity in the left amygdala-hippocampal complex and increased activity in the left parahippocampal gyrus, suggesting that CBD's anxiolytic properties are mediated by its action on limbic and paralimbic brain areas .
In adults with ASD, CBD has been shown to increase low-frequency activity in the cerebellar vermis and right fusiform gyrus. This effect is primarily driven by the ASD group, indicating that CBD may alter regional brain activity and connectivity in ways that are particularly relevant to ASD.
CBD has been found to modulate excitatory glutamate and inhibitory GABA levels in the brain. In neurotypical individuals, CBD increases subcortical glutamate and GABA levels, while in individuals with ASD, it decreases cortical GABA levels. These findings suggest that CBD's effects on neurotransmitter systems may vary depending on the presence of neurodevelopmental disorders.
CBD has demonstrated neuroprotective effects in models of brain damage, such as hypoxic-ischemic conditions in newborn mice. These effects are mediated by CB2 and adenosine receptors, highlighting CBD's potential in reducing brain damage and promoting neurogenesis. Additionally, in chronically stressed mice, CBD's anxiolytic effects are linked to increased hippocampal neurogenesis and dendritic remodeling, mediated through CB1 and CB2 receptors.
Systematic reviews have indicated that both acute and chronic administration of CBD does not impair cognitive processing in humans without neuropsychiatric disorders. In fact, CBD may improve cognitive function in individuals who use cannabis heavily, although its effects on those with neuropsychiatric disorders remain to be fully elucidated.
In individuals at clinical high risk of psychosis, CBD has been shown to partially normalize brain activation in regions such as the parahippocampal gyrus, striatum, and midbrain. These regions are critical to the pathophysiology of psychosis, suggesting that CBD's influence on these areas could underlie its therapeutic effects on psychotic symptoms.
CBD exhibits a range of effects on brain function, including enhanced connectivity, modulation of regional cerebral blood flow, and neurotransmitter systems. Its anxiolytic, neuroprotective, and potential cognitive benefits make it a promising candidate for treating various neuropsychiatric and neurodevelopmental disorders. Future research should focus on long-term effects and the mechanisms underlying CBD's therapeutic potential.
Most relevant research papers on this topic